Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter regimens.

Autor: Gospodarevskaya E; Liverpool School of Tropical Medicine, Liverpool, UK., Tulloch O; Liverpool School of Tropical Medicine, Liverpool, UK., Bunga C; National Institute for Medical Research, Mwanza, Tanzania., Ferdous S; BRAC Health Nutrition and Population Programme, BRAC Centre, Dhaka, Bangladesh., Jonas A; National Institute for Medical Research, Mwanza, Tanzania., Islam S; BRAC Health Nutrition and Population Programme, BRAC Centre, Dhaka, Bangladesh., Rahman M; National Tuberculosis Control Programme, Dhaka, Bangladesh., Hussain MA; National Tuberculosis Control Programme, Dhaka, Bangladesh., Haque MN; National Tuberculosis Control Programme, Dhaka, Bangladesh., Egwaga S; National Tuberculosis and Leprosy Programme, Ministry of Health and Social Welfare, Dar es Salaam, Tanzania., Gardiner E; TB Alliance, New York, New York, USA., PrayGod G; National Institute for Medical Research, Mwanza, Tanzania., Islam MA; BRAC Health Nutrition and Population Programme, BRAC Centre, Dhaka, Bangladesh., Mann GH; Liverpool School of Tropical Medicine, Liverpool, UK., Wells WA; TB Alliance, New York, New York, USA., Squire SB; Liverpool School of Tropical Medicine, Liverpool, UK.
Jazyk: angličtina
Zdroj: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease [Int J Tuberc Lung Dis] 2014 Jul; Vol. 18 (7), pp. 810-7.
DOI: 10.5588/ijtld.13.0391
Abstrakt: Objective: To estimate the costs incurred by patients during the intensive and continuation phases of the current 6-month tuberculosis (TB) regimen in Bangladesh and Tanzania, and thus identify potential benefits to patients of a shorter, 4-month treatment regimen.
Design: The validated Stop TB patient cost questionnaire was adapted and used in interviews with 190 patients in the continuation phase of treatment with current regimens.
Results: In both countries, overall patient costs were lower during 2 months of the continuation phase (US$74 in Tanzania and US$56 in Bangladesh) than during the 2 months of the intensive phase of treatment (US$150 and US$111, respectively). However, continuation phase patient costs still represented 89% and 77% of the 2-month average national income in the respective countries. Direct travel costs in some settings were kept low by local delivery system features such as community treatment observation. Lost productivity and costs for supplementary foods remained significant.
Conclusions: Although it is not a straightforward exercise to determine the exact magnitude of likely savings, a shorter regimen would reduce out-of-pocket expenses incurred by patients in the most recent 2 months of the continuation phase and allow an earlier return to productive activities.
Databáze: MEDLINE
Externí odkaz: